serum samples; serum exosomes; cellular extracts
A549; AT2 cell
-
not specified (other)
Clinical Sample Validation
hsa_circ_0003026 shows promise as a non-invasive diagnostic biomarker for NSCLC and may support liquid biopsy-based diagnosis and disease monitoring.
This study developed and applied a CRISPR/Cas13a-induced self-priming cyclic amplification assay to detect exosomal hsa_circ_0003026. hsa_circ_0003026 was significantly upregulated in serum exosomes from NSCLC patients compared with healthy controls, supporting its potential as a liquid biopsy biomarker for NSCLC diagnosis.
0.208
CRISPR/Cas13a-induced self-priming cyclic amplification enables liquid biopsy of exosomal circular RNA in non-small cell lung cancer.
combined method development and clinical study